Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan versus enalapril for pulmonary resistance in heart failure with reduced ejection fraction
2020-006072-32Phase 4Active
- Sponsor
- Uniwersytecki Szpital Kliniczny w Poznaniu
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sacubitril + valsartan and enalapril in heart failure with reduced ejection fraction (HFrEF) and pulmonary hypertension (PH) (2 arms), sponsored by Uniwersytecki Szpital Kliniczny w Poznaniu. Primary endpoint: Change from baseline in mean pulmonary artery pressure. Started Jan 2021; status: active.
02
Drugs
sacubitril + valsartanenalapril
03
Conditions
heart failure with reduced ejection fraction (HFrEF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2020-006072-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006072-32.